BRPI0512042A - composição imunogênica, vacina, métodos de evitar infecção e/ou doença por hpv, de produzir uma composição imunogênica e de prevenir ou tratar infecção e/ou doença por hpv - Google Patents

composição imunogênica, vacina, métodos de evitar infecção e/ou doença por hpv, de produzir uma composição imunogênica e de prevenir ou tratar infecção e/ou doença por hpv

Info

Publication number
BRPI0512042A
BRPI0512042A BRPI0512042-0A BRPI0512042A BRPI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A BR PI0512042 A BRPI0512042 A BR PI0512042A
Authority
BR
Brazil
Prior art keywords
disease
immunogenic composition
preventing
hpv infection
methods
Prior art date
Application number
BRPI0512042-0A
Other languages
English (en)
Inventor
Serge Debrus
Marie-Therese Martin
Robert John Stephen
Jean Stephenne
Martine Anne Cecil Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0512042A publication Critical patent/BRPI0512042A/pt
Publication of BRPI0512042B1 publication Critical patent/BRPI0512042B1/pt
Publication of BRPI0512042B8 publication Critical patent/BRPI0512042B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSIçãO IMUNOGêNICA, VACINA, MéTODOS DE EVITAR INFECçãO E/OU DOENçA POR HPV, DE PRODUZIR UMA COMPOSIçãO IMUNOGêNICA E DE PREVENIR OU TRATAR INFECçãO E/OU DOENçA POR HPV Uma composição imunogênica e métodos para produzir dita composição, a composição compreendendo VLPs de HPV 16 e 18 e pelo menos um outro tipo de câncer HPV, o outro tipo de câncer sendo selecionado da lista consistindo de I-IPV tipos 31, 45 e 52, em que a dose do VLP do pelo menos um outro tipo de câncer é reduzida àquela do HPV 16 ou 18.
BRPI0512042A 2004-06-16 2005-06-14 composição imunogênica, vacina, uso de uma composição ou vacina, método para produzir uma composição imunogênica, e, uso de vlps ou capsômeros de hpv 16 e 18 com vlps ou capsômeros de pelo menos um outro hpv do tipo causador de câncer BRPI0512042B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (3)

Publication Number Publication Date
BRPI0512042A true BRPI0512042A (pt) 2008-02-06
BRPI0512042B1 BRPI0512042B1 (pt) 2019-01-22
BRPI0512042B8 BRPI0512042B8 (pt) 2021-05-25

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512042A BRPI0512042B8 (pt) 2004-06-16 2005-06-14 composição imunogênica, vacina, uso de uma composição ou vacina, método para produzir uma composição imunogênica, e, uso de vlps ou capsômeros de hpv 16 e 18 com vlps ou capsômeros de pelo menos um outro hpv do tipo causador de câncer

Country Status (18)

Country Link
EP (1) EP1758609B1 (pt)
JP (1) JP2008502633A (pt)
KR (1) KR20070029254A (pt)
AR (1) AR049354A1 (pt)
AU (1) AU2005253723B2 (pt)
BR (1) BRPI0512042B8 (pt)
CA (1) CA2566620C (pt)
FR (2) FR15C0084I2 (pt)
IL (1) IL179138A0 (pt)
LU (3) LU92899I2 (pt)
MA (1) MA28692B1 (pt)
MX (1) MXPA06014515A (pt)
NO (1) NO20070195L (pt)
PE (1) PE20060434A1 (pt)
PL (1) PL1758609T3 (pt)
RU (1) RU2420313C2 (pt)
SG (1) SG153837A1 (pt)
WO (1) WO2005123125A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
CN102159239A (zh) * 2008-07-31 2011-08-17 葛兰素史密斯克莱生物公司 针对hpv的疫苗
CN104288763B (zh) * 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
AU2011279365A1 (en) * 2010-07-15 2013-03-07 British Columbia Cancer Agency Branch Human papillomavirus E7 antigen compositions and uses thereof
CA2885145A1 (en) 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Also Published As

Publication number Publication date
LU92899I2 (fr) 2016-03-08
JP2008502633A (ja) 2008-01-31
LU92900I2 (fr) 2016-03-08
AU2005253723B2 (en) 2011-01-20
FR15C0084I1 (pt) 2016-01-08
NO20070195L (no) 2007-01-15
SG153837A1 (en) 2009-07-29
CA2566620A1 (en) 2005-12-29
EP1758609B1 (en) 2012-10-03
KR20070029254A (ko) 2007-03-13
MA28692B1 (fr) 2007-06-01
EP1758609A1 (en) 2007-03-07
PL1758609T3 (pl) 2013-02-28
AR049354A1 (es) 2006-07-19
MXPA06014515A (es) 2007-03-23
LU92898I2 (fr) 2016-03-08
CA2566620C (en) 2014-03-11
PE20060434A1 (es) 2006-06-08
FR15C0082I2 (fr) 2016-10-28
FR15C0082I1 (fr) 2016-01-08
WO2005123125A1 (en) 2005-12-29
AU2005253723A1 (en) 2005-12-29
RU2420313C2 (ru) 2011-06-10
BRPI0512042B1 (pt) 2019-01-22
FR15C0084I2 (fr) 2016-10-28
BRPI0512042B8 (pt) 2021-05-25
IL179138A0 (en) 2007-03-08
RU2006143804A (ru) 2008-08-20

Similar Documents

Publication Publication Date Title
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
PH12019550113A1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
UA106365C2 (ru) Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
CL2008003822A1 (es) Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer.
BR112016014668A2 (pt) Método para sintetizar um polímero de poliacrilonitrila, polímero de poliacrilonitrila, e, método para produzir uma fibra de carbono
GEP20146134B (en) Inhibitors of hepatitis c virus replication
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR071003A1 (es) Farmaco contra cancer de higado
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
BRPI0507198A (pt) derivados de bisariluréia
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
BR112012008325A2 (pt) N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
BR112022021957A2 (pt) Imidazopirimidinas como moduladores de il -17

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/06/2025.